Table 1. Patient and treatment characteristics.

Progression-free survival (PFS); re-treatment, post-recurrence survival (PRS) and post-recurrence progression-free survival (PR-PFS); GB—glioblastoma, AA—anaplastic astrocytoma, GTR—gross total resection, STR—subtotal resection, RT—radiotherapy, RCX—radiochemotherapy, BEV—bevacizumab, TMZ—temozolomide, PDT—photodynamic therapy.

Pt	Patient Characteristics	Primary Treatment	PFS [months]	Re-Treatment	PR-PFS [months]	PRS [months]
1	62 y, male, GB, right temporal lobe, MGMT unmethylated, IDH1-wildtype	GTR, RCX with TMZ, adj. TMZ	11	re-RT with BEV, BEV maintenance	7	13
2	47 y, male, AA, left frontal lobe, MGMT methylated, IDH1-wildtype	STR, RCX with TMZ, adj. TMZ	40	re-RT with BEV	0	0 (lost to follow up)
3	69 y, male, GB, left frontal lobe, MGMT unmethylated, IDH1-wildtype	Biopsy, PDT, RCX with TMZ, adj. TMZ	14	re-RT with BEV, BEV maintenance	2	2
4	54 y, male, GB, left temporal lobe, MGMT methylated, IDH1-wildtype	Biopsy, RCX with TMZ, adj. TMZ	9	STR, re-RT with BEV, BEV maintenance	8	33
5	46 y, male, GB, left parietal lobe, MGMT unmethylated, IDH1-wildtype	GTR, RCX with TMZ, adj. TMZ, Seeds, PDT	36	re-RT with TMZ, Seeds	8	26
6	34 y, male, AA, left frontal lobe, MGMT methylated, IDH1 mutated	GTR, RCX with ACNU/Teniposid, STR, adj. TMZ, Seeds, TMZ	125	re-RT with BEV, BEV maintenance, TMZ, Novo-TTF	10	25
7	61 y, male, GB, left temporal lobe, MGMT unmethylated, IDH1-wildtype	GTR, RT	10	re-RT with BEV	3	5